Physician profile
Brian Steg
NPI 1821050782
$3,081.04
in general payments reported to CMS, 2019-2025
33 companies · $31.90 in 2025
The $31.90 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,514 · 2020: $495 · 2021: $158 · 2022: $717 · 2023: $80.09 · 2024: $86.11 · 2025: $31.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $198.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $494.89 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $411.89 | 2019-2022 | |
| Abbott Laboratories | $298.92 | 2019-2025 | Aveir |
| Novartis Pharmaceuticals Corporation | $282.74 | 2019-2024 | |
| Pfizer INC. | $189.30 | 2019-2023 | |
| Medtronic, INC. | $182.18 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $139.18 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $119.46 | 2019-2023 | Camzyos |
| Chiesi USA, INC. | $111.48 | 2019-2021 | |
| Cardinal Health 200 LLC | $89.05 | 2020 | |
| Medtronic Vascular, INC. | $88.83 | 2019 | |
| Sanofi-Aventis U.S. LLC | $65.13 | 2019-2020 | |
| Penumbra, INC. | $64.64 | 2019 | |
| Merck Sharp & Dohme LLC | $48.37 | 2021-2024 | Verquvo |
| Portola Pharmaceuticals, LLC | $46.95 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $40.26 | 2019-2020 | |
| Bardy Diagnostics, INC. | $36.00 | 2019 | |
| Arbor Pharmaceuticals, INC. | $35.61 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.60 | 2019-2022 | |
| Scpharmaceuticals INC. | $35.44 | 2024 | |
| Astellas Pharma US INC | $33.27 | 2019-2020 | |
| Amarin Pharma, INC. | $30.66 | 2019-2020 | |
| Boston Scientific Corporation | $28.79 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.62 | 2023 | Lifevest |
| Abiomed | $22.11 | 2019 | |
| Cook Medical LLC | $20.18 | 2022 | |
| Nuwellis, INC. | $18.34 | 2019 | |
| Biotronik INC. | $18.29 | 2019 | |
| Elutia, INC. | $15.47 | 2022 | |
| Novo Nordisk INC | $15.37 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.86 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $12.11 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Steg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.